IsoPSA Blood Test Shows Promising Results for Early Prostate Cancer Diagnosis

IsoPSA Blood Test Shows Promising Results for Early Prostate Cancer Diagnosis
IsoPSA, a blood test developed by Cleveland Diagnostics that detects cancer-derived PSA, is more accurate in diagnosing prostate cancer than a conventional PSA test and reduces the need for biopsies by nearly half, according to the results of a U.S.-based study. The findings were published in the journal European Urology under the title, "The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report." IsoPSA is still the focus of studies and has not been approved for use in the United States. "The IsoPSA test provides two necessary parameters for a successful test: specificity of the organ's tissue and specificity of the cancer. The trial proved that it is more accurate in diagnosing cancer and lowering the number of unnecessary biopsies among patients at low risk to the disease," Eric Klein, MD, chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic in Ohio, said in a press release. Prostate-specific antigen (PSA) is a protein produced by the prostate gland and secreted into semen. It can be measured in the blood as an indicator of diseases affecting the prostate gland
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *